Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

60.77 +3.27 (+5.69%)

Streaming Delayed Price Updated: 3:43 PM EDT, May 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,254,648
Open	58.68
Bid (Size)	60.51 (800)
Ask (Size)	60.80 (200)
Prev. Close	57.50
Today's Range	56.74 - 60.91
52wk Range	9.540 - 91.00
Shares Outstanding	14,410,143
Dividend Yield	31.85%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗

May 13, 2026

This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.

Via The Motley Fool

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗

May 13, 2026

This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.

Via The Motley Fool

Performance

YTD	+115.0%	+115.0%
1 Month	-11.8%	-11.8%
3 Month	+86.0%	+86.0%
6 Month	+121.4%	+121.4%
1 Year	+489.4%	+489.4%

More News

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗

May 13, 2026

Via The Motley Fool

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? ↗

May 11, 2026

Via The Motley Fool

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

April 28, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

April 27, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

These stocks are gapping in today's session ↗

April 27, 2026

Via Chartmill

Top movers in Monday's pre-market session ↗

April 27, 2026

Via Chartmill

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

April 27, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

April 26, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors ↗

April 21, 2026

Via The Motley Fool

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

Via The Motley Fool

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

Via The Motley Fool

Let's take a look at the stocks that are in motion in today's session. ↗

March 13, 2026

Via Chartmill

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 12, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

February 09, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

January 12, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces New Board Member and Board Transition

December 11, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 13, 2025

Via Benzinga

AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 13, 2025

Via Benzinga

Oruka Therapeutics Inc (NASDAQ:ORKA) Reports Q3 2025 Results, Beats EPS Estimates and Provides Clinical Pipeline Updates ↗

November 12, 2025

Via Chartmill

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Oruka Therapeutics, Inc. - Common Stock publicly traded?

Yes, Oruka Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Oruka Therapeutics, Inc. - Common Stock trade on?

Oruka Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Oruka Therapeutics, Inc. - Common Stock?

The ticker symbol for Oruka Therapeutics, Inc. - Common Stock is ORKA on the Nasdaq Stock Market

What is the current price of Oruka Therapeutics, Inc. - Common Stock?

The current price of Oruka Therapeutics, Inc. - Common Stock is 60.77

When was Oruka Therapeutics, Inc. - Common Stock last traded?

The last trade of Oruka Therapeutics, Inc. - Common Stock was at 05/20/26 03:43 PM ET

What is the market capitalization of Oruka Therapeutics, Inc. - Common Stock?

The market capitalization of Oruka Therapeutics, Inc. - Common Stock is 875.70M

How many shares of Oruka Therapeutics, Inc. - Common Stock are outstanding?

Oruka Therapeutics, Inc. - Common Stock has 876M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.